

Department of Radiation Oncology

Monthly Research Update: July 2024

UM Radiation Oncology at AAPM 2024

JULY AT A GLANCE TOTALS

Clinical trials

Total enrolled	30
GCC, other	7
NRG, NCI, co-ops	2
PCG, other registries	21

Grants and contracts

New awards	2
Submitted	1

Articles published

5

On June 25, 2024, the National Library of Medicine's (NLM's) [modernized ClinicalTrials.gov website](#) became the only available NIH clinical trials site, with the retirement of the classic version of the site and its application programming interface. For 1 year, the new site ran in parallel with the classic version of the ClinicalTrials.gov website. Attempts to access the classic site, including some frequently used links, will now automatically be redirected to the modernized ClinicalTrials.gov website. The updated platform, designed with user feedback to accommodate growth and enhance efficiency, features improved functionality for searching, viewing, and downloading information about more than 490,000 current and past clinical trials, observational studies, and expanded access programs. According to an NLM press release, the new streamlined site includes simple web components that improve navigation, as well as optimization for mobile devices, plain-language guidance and support materials, and an updated interface that aligns with other publicly accessible interfaces and standardized data. Additional features are planned for 2024 release.

An important note for both researchers and the public looking to identify trials in their areas of interest is that search results are not the same on the modernized website. New search results are "more targeted and refined," synonym recognition is more precise using the new algorithm's search logic, and, when the user's location is specified, results are biased by proximity to the closest location for every study. A [Search Areas](#) page describes the ClinicalTrials.gov search logic. For more information, see [Modernization Transition Top Questions](#). To learn more about the modernization effort and stay informed about future updates, visit the [ClinicalTrials.gov Modernization](#) webpage and the latest [Release Notes](#).

Information for this monthly update should be provided no later than the second Wednesday of each month to Miek Segers at msegers@som.umaryland.edu. The update will be published on the second Friday of each month.

Have questions about identifying a funding source? Finding research partners across the UMB/UM campuses or at another university? Defining future research strategies? Or organizing your thoughts on (virtual) paper? Contact Nancy Knight, PhD, Director of Academic and Professional Development for the department, at nknight@umm.edu

Clinical Trial Enrollment

- 20 patients at MPTC on the **Proton Collaborative Group Registry**
- 1 patient at MPTC on the **DTT HUD**
- 2 patients at UMMC on **GCC 2380**: A single arm phase II trial evaluating selective adjuvant therapy for HPV-mediated oropharynx SCCs based on residual circulating tumor DNA levels (SAVAL)
- 1 patient at BWMC on **NRG GU010**: Parallel phase III randomized trials of genomic risk stratified unfavorable intermediate risk prostate cancer: De-intensification and intensification clinical trial evaluation (guidance)
- 1 patient at BWMC on **NRG BR007**: A phase III clinical trial evaluating de-escalation of breast radiation for conservative treatment of stage I, hormone sensitive, HER-2 negative, oncotype recurrence score less than or equal to 18 breast cancer
- 2 patients at UMMC on **GCC 2384**: Evaluation of improved onboard patient imaging with the Varian HyperSight platform on Truebeam 4.1
- 1 patient at UMMC on **GCC 23100**: A randomized trial of high-risk metachronous oligometastatic prostate cancer with high-risk mutations treated with metastasis directed therapy and niraparib/abiraterone and prednisone (KNIGHTS)
- 1 patient at Shore on **CCTG MA.39**: Tailor RT: A randomized trial of regional radiotherapy in biomarker low risk node positive and T3N0 breast cancer
- 1 patient at MPTC on **GCC 19140**: Pilot study of laser interstitial thermal therapy followed by hypofractionated radiation therapy for treatment of recurrent gliomas

Grants and Contracts

Funded

- **Melissa Vyfhuis, MD, PhD, PI**, from the Robert E. Meyerhoff Foundation, Inc. for “Practical interventions to help improve cancer care for patients who live in food priority areas (FPAs) or food deserts”. (\$149,270).
- **Jason Molitoris, MD, PhD, PI clinical study**, for Varian Medical Systems Inc., for “Evaluation of improved onboard patient imaging with the Varian HyperSight platform on TrueBeam 4.0/4.1” (\$130,504).

Submitted

- **Hem Shukla, PhD, PI**, on a Maryland Stem Cell Research Fund Launch Program FY25: “Investigate hypoxia-induced aberrant activation of OCT4 and SOX2 in adult pancreatic stem cells and their role in malignant transformation employing pancreas organoid model” (\$348,450).

Articles Published

Entered into PubMed July 12-August 8. Titles link to PubMed abstracts, many of which contain full-text links.

1. **Cao Y**, Sutera P, **Silva Mendes W**, Yousefi B, Hrinivich T, Deek M, Phillips R, Song D, Kiess A, Cem Guler O, Torun N, Reyhan M, **Sawant A**, Marchionni L, Simone NL, **Tran P**, Onal C, **Ren L**. [Machine learning predicts conventional imaging metastasis-free survival \(MFS\) for oligometastatic castration-sensitive prostate cancer \(omCSPC\) using prostate-specific membrane antigen \(PSMA\) PET radiomics](#). *Radiother Oncol*. 2024 Jul 31;199:110443.
2. Deng Z, Xu X, Dehghani H, Reyes J, Zheng L, **Tran PT**, Wang KK-H. [In vivo bioluminescence tomography-guided system for pancreatic cancer radiotherapy research](#). *Biomed Opt Express*. 2024;15(8):4525-4539.
3. Kachnic LA, Winter K, **Suntharalingam M**, Ilson D, Konski A, Lloyd S, **McAvoy SA**, Lad T, Olowokure OG, Samson P, Gore EM, Meyer JE, Videtic GMM, Clump DA, Raben A, Kayaleh O, Barker J Jr, Haddock MG, Hopkins JO, Bruner DW. [Patient-reported outcomes \(PROs\) in NRG Oncology RTOG 0436: a phase III trial evaluating the addition of cetuximab to paclitaxel, cisplatin, and radiation for esophageal cancer treated without surgery](#). *Qual Life Res*. 2024 Jul 27. Online ahead of print.
4. Sutera P, Kim J, Kumar R, Deek RA, Stephenson R, Mayer T, Saraiya B, Ghodoussipour S, Jang T, Golombos D, Packiam V, Ennis R, Hathout L, Jabbour SK, Guler O, Onal C, **Tran PT**, Deek MP. [PIK3/Akt/mTOR pathway alterations in metastatic castration-sensitive prostate cancer](#). *Prostate*. 2024 Jul 17. Online ahead of print.
5. **Xu J, Zhang B, Guerrero M, Kalavagunta C, Chen S, Xu H**. [Technical note: An automated document verification tool in radiation oncology EMR: Application for LDR prostate brachytherapy](#). *J Appl Clin Med Phys*. 2024 Jul 30:e14466. Online ahead of print.

Important Dates for Upcoming Funding Submissions

Below is an updated calendar with firm due dates for upcoming major standard NIH deadlines (RFA/PA dates may differ). Contact the Department Office of Research Administration (msegers@som.umaryland.edu) ASAP if you plan to submit any funding proposal, regardless of funder.

NIH deadline	DORA budget, prelim materials	Dean/SOM prelim materials	FINAL Dean/SOM/SPA
R01/U01 New Oct 5	09/24/2024	09/26/2024	09/30/2024
R21 New Oct 16	10/03/2024	10/07/2024	10/09/2024
R01/U01 Resub Nov 5	10/23/2024	10/25/2024	10/29/2024
R21 Resub Nov 16	11/05/2024	11/07/2024	11/11/2024

From NIH: Reminder on formatting for resubmissions: As May 25, 2024, NIH is no longer requiring nor permitting the use of any markups (including bracketing, indenting, highlighting, bolding, italicizing, underlining, margin lines, and change in typography, font, or font color) to identify changes in resubmission applications. The new instructions are: “Changes made to a resubmission application should only be outlined in the introduction attachment. The introduction must include a summary of substantial additions, deletions, and changes to the application. It must also include a response to weaknesses raised in the summary statement.” [See NOT-OD-24-061](#).